Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2022-08-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于S086临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the progress of a Phase III clinical trial for their drug S086. It provides detailed information about the clinical trial enrollment completion, drug characteristics, and future plans. The document is relatively short (997 characters) and is an update on clinical trial progress rather than a financial report or regulatory filing. It does not contain financial statements, earnings data, or governance information. It is not a report publication announcement since it contains substantive information about the clinical trial progress. The content fits best under a general regulatory announcement category as it is a company disclosure about clinical trial progress, which does not fit into other specific financial or governance categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-08-16 Chinese
关于SAL0112获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a clinical trial for their drug SAL0112. It contains no financial data, no discussion of financial results, no management or board changes, no voting results, and no regulatory certifications. The document is an official company announcement about a regulatory approval event related to clinical trials, which is a typical regulatory announcement. The document length is short (1427 characters), and it is not a report or presentation but an announcement of a specific event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-08-16 Chinese
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司2022 年半年度报告" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2022 Semi-Annual Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2022. The report explicitly states it is a half-year financial report and includes comprehensive financial data and analysis for the period. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-09 Chinese
第五届监事会第二十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of the company's 2022 semi-annual report and a special report on the use of raised funds. It states that the semi-annual report and related financial reports are available on external disclosure platforms, indicating this document itself is not the full semi-annual report but an announcement of the Supervisory Board's approval of these reports. The document is short (1205 characters) and primarily serves as a formal announcement of meeting resolutions rather than containing substantive financial data or the full report. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory announcement rather than the Interim/Quarterly Report (IR) itself or a Report Publication Announcement (RPA) because it includes the Supervisory Board's resolution details and assurances about the report's compliance and accuracy.
2022-08-09 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the first half of 2022 by Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes financial figures such as balances, amounts occupied, interest, and repayments. The content is financial in nature but very specific to related party transactions and fund occupation rather than a full financial report. The document length is short (1537 characters) and it is a detailed financial summary rather than an announcement or a certification. It does not contain comprehensive financial statements or management discussion. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory disclosure of related party fund usage and not a full interim report or annual report.
2022-08-09 Chinese
第五届董事会第三十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. It details the approval of the company's 2022 semi-annual report and related financial reports by the board of directors. The document includes voting results and references to where the full reports can be found but does not contain the full financial statements or detailed financial data itself. The document length is short (1061 characters) and serves as an announcement of the board's resolutions rather than the report itself. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2022-08-09 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.